Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Nuclear
Kontrolle:Tonsil, lymphoma
Synonyme:Antigen identified by monoclonal antibody Ki 67, Antigen KI67, KIA, Ki-67, Ki67, MKI67, Proliferation related Ki 67 antigen.
Verfügbar in folgenden Ländern:worldwide

Ki-67 is a nuclear protein expressed in all proliferating cells, which are in active phases of cell cycle (late G1, S, G2, mitosis). Ki-67 is not detected in resting cells (G0 phase). Thus, the antibody is a general proliferation marker, especially used to assess the proliferative activity of a tumor. Different cancer types express Ki-67, including breast, prostate, lung, and colon.


[1] Bacus SS, Goldschmidt R, Chin D, Moran G et al. (1989): Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am J Pathol. 135(5): 783-792.
[2] Buhmeida A, Pyrhönen S, Laato M and Collan Y (2006): Prognostic factors in prostate cancer. Diagn Pathol. 1: 4.
[3] Soliman ML, Tiwari A and Zhao Q (2017): Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin. World J Gastroenterol. 23(6): 1106-1112.
[4] Kriegsmann M and Warth A (2016): Ki-67 expression in pulmonary tumors-reply. Transl Lung Cancer Res. 5(5): 552-553.